Preview

Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice

Advanced search

Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices - Modeling Studies

Abstract

Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices - Modeling Studies Abstract. Objectives: Mathematical modeling is used widely in economic evaluations of pharmaceuticals and other healthcare technologies. Users of models in government and the private sector need to be able to evaluate the quality of models according to scientific criteria of good practice. This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies. Methods: The task force was appointed with the advice and consent of the Board of Directors of ISPOR. Members were experienced developers or users of models, worked in academia and industry, and came from several countries in North America and Europe. The task force met on three occasions, conducted frequent correspondence and exchanges of drafts by electronic mail, and solicited comments on three drafts from a core group of external reviewers and more broadly from the membership of ISPOR. Results: Criteria for assessing the quality of models fell into three areas: model structure, data used as inputs to models, and model validation. Several major themes cut across these areas. Models and their results should be represented as aids to decision making, not as statements of scientific fact; therefore, it is inappropriate to demand that models be validated prospectively before use. However, model assumptions regarding causal structure and parameter estimates should be continually assessed against data, and models should be revised accordingly. Structural assumptions and parameter estimates should be reported clearly and explicitly, and opportunities for users to appreciate the conditional relationship between inputs and outputs should be provided through sensitivity analyses. Conclusions: Model-based evaluations are a valuable resource for health-care decision makers. It is the responsibility of model developers to conduct modeling studies according to the best practicable standards of quality and to communicate results with adequate disclosure of assumptions and with the caveat that conclusions are conditional upon the assumptions and data on which the model is built.

About the Authors

M. C. Weinstein
Center for Risk Analysis, Harvard School of Public Health; Innovus Research, Inc
United States


Bernie O’Brien
McMaster University
Canada


John Hornberger
Acumen, LLC; Stanford University School of Medicine
United States


Joseph Jackson
Pharmaceutical Research Institute
United States


Magnus Johannesson
Centre for Health Economics, Stockholm School of Economics
Sweden


Chris Mccabe
Trent Institute for Health Services Research, University of Sheffield
United Kingdom


Bryan R. Luce
MEDTAP International
United States


A. V. Pavlysh
First Pavlov State Medical University of Saint Petersburg, Saint Petersburg, Russia
Russian Federation


A. S. Kolbin
First Pavlov State Medical University of Saint Petersburg, Saint Petersburg, Russia; Saint Petersburg State University, Saint Petersburg, Russia
Russian Federation


References

1. National Research Council. Improving Information for Social Policy Decisions: The Uses of Microsimulation Modeling, Vol. 1, Review and Recommendations. Washington: National Academy Press; 1991.

2. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4: 348-61.

3. Sculpher M., Fenwick E., Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17:461-77.

4. Hay J., Jackson J., Luce B., et al. Methodological issues in conducting pharmacoeconomic evaluations-modeling studies. Value Health 1999; 2:78-81.

5. Akehurst R., Anderson P., Brazier J., et al. Decision analytic modeling in the economic evaluation of health technologies. Pharmacoeconomics 200.0;17: 443-4.

6. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. Report of the Panel on Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.

7. Hunink M., Glasziou P., Siegel J., et al. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge: Cambridge University Press; 2001.

8. Kuntz K., Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001.

9. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001.


Review

For citations:


Weinstein M.C., O’Brien B., Hornberger J., Jackson J., Johannesson M., Mccabe Ch., Luce B.R., Pavlysh A.V., Kolbin A.S. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2015;(2):19-28. (In Russ.)

Views: 1021


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)

  

OSZAR »